Literature DB >> 7131022

Treatment of the Guillain-Barré syndrome by plasma exchange.

C Kennard, A C Newland, A Ridley.   

Abstract

Twelve consecutive patients with Guillain-Barré syndrome were treated with plasma exchange. Examination two weeks after treatment was commenced showed that three had not improved. Five showed only a minimal improvement, which was considered to be compatible with the natural history of the disease. The remaining four patients showed a more substantial improvement which could have been related to the plasma exchange.

Entities:  

Mesh：

Year:  1982        PMID： 7131022      PMCID： PMC491573          DOI： 10.1136/jnnp.45.9.847

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  13 in total

1.  The occurrence of IgM and complement factors along myelin sheaths of peripheral nerves. An immunohistochemical study of the Guillain-Barré syndrome. Preliminary communication.

Authors:  J A Luijten
Journal:  J Neurol Sci       Date:  1972-02       Impact factor: 3.181

2.  Circulating demyelinating factors in acute idiopathic polyneuropathy.

Authors:  S D Cook; P C Dowling; M R Murray; J N Whitaker
Journal:  Arch Neurol       Date:  1971-02

3.  Landry-Guillain-Barré syndrome. A primary demyelinating disease.

Authors:  H Wiśniewski; R D Terry; J N Whitaker; S D Cook; P C Dowling
Journal:  Arch Neurol       Date:  1969-09

4.  Abnormal T cell subpopulations and circulating immune complexes in the Guillain-Barré syndrome and multiple sclerosis.

Authors:  J M Goust; F Chenais; J E Carnes; C G Hames; H H Fudenberg; E L Hogan
Journal:  Neurology       Date:  1978-05       Impact factor: 9.910

5.  Treatment of acute polyneuropathy by plasma exchange.

Authors:  R P Brettle; M Gross; N J Legg; M Lockwood; C Pallis
Journal:  Lancet       Date:  1978-11-18       Impact factor: 79.321

6.  Plasma exchange in Guillain-Barré syndrome.

Authors:  W F Durward; A K Burnett; R Watkins; J M Reid
Journal:  Br Med J (Clin Res Ed)       Date:  1981-09-19

7.  Criteria for diagnosis of Guillain-Barré syndrome.

Authors: 
Journal:  Ann Neurol       Date:  1978-06       Impact factor: 10.422

8.  Plasma exchange as a therapy for Guillain-Barré syndrome with immune complexes.

Authors:  M Valbonesi; S Garelli; L Mosconi; D Zerbi; I Celano
Journal:  Vox Sang       Date:  1981       Impact factor: 2.144

9.  Controlled trial prednisolone in acute polyneuropathy.

Authors:  R A Hughes; J M Newsom-Davis; G D Perkin; J M Pierce
Journal:  Lancet       Date:  1978-10-07       Impact factor: 79.321

10.  Transient hypoxaemia during sleep in chronic bronchitis and emphysema.

Authors:  N J Douglas; P M Calverley; R J Leggett; H M Brash; D C Flenley; V Brezinova
Journal:  Lancet       Date:  1979-01-06       Impact factor: 79.321
View more
  6 in total

1.  The treatment of Guillain-Barré syndrome by modified plasma exchange--a cost effective method for developing countries.

Authors:  H J De Silva; R Gamage; H K Herath; M G Karunanayake; J B Peiris
Journal:  Postgrad Med J       Date:  1987-12       Impact factor: 2.401

2.  The treatment of acute polyneuropathy by plasma exchange.

Authors:  M L Gross
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-04       Impact factor: 10.154

3.  Treatment of peripheral neuropathies.

Authors:  M Hallett; D Tandon; A Berardelli
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-12       Impact factor: 10.154

4.  Guillain-Barre syndrome: a series observed at Riyadh Armed Forces Hospital January 1984--January 1994.

Authors:  Y G Bahou; N Biary; S al Deeb
Journal:  J Neurol       Date:  1996-02       Impact factor: 4.849

5.  Clinical effects of plasmapheresis in acute Guillain-Barré syndrome.

Authors:  G Piccolo; V Cosi; M Lombardi; M Poloni; M Ceroni; P M Fornasari
Journal:  Ital J Neurol Sci       Date:  1986-06

6.  Plasma exchange for Guillain-Barré syndrome.

Authors:  J Tharakan; R E Ferner; R A Hughes; J Winer; M Barnett; E R Brown; G Smith
Journal:  J R Soc Med       Date:  1989-08       Impact factor: 18.000
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.